首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1289782

全球宮頸癌診斷市場 - 2023-2030年

Global Cervical Cancer Diagnostics Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球宮頸癌診斷市場的規模在2022年達到81億美元，預計到2030年將見證有利可圖的成長，達到130億美元。在2023-2030年的預測期內，宮頸癌診斷市場預計將呈現6.3%的複合成長率。

作為宮頸癌診斷的一部分，各種測試和技術被用於診斷和監測宮頸癌和癌前疾病。額外的程序，如淋巴結活檢、膀胱鏡、直腸鏡或PET-CT（正電子發射斷層掃描-電腦斷層掃描）等成像測試，被用來確定宮頸癌的階段。

市場動態

活躍的主要參與者和宮頸癌診斷產品的推出，在預測期內推動了全球宮頸癌診斷市場的成長。

對於女性來說，宮頸癌是一種典型的惡性腫瘤。近年來，隨著發病率和死亡率的增加，出現了明顯的年輕化趨勢。唯一有明確病因並可通過早期檢測治癒的癌症是宮頸癌。例如，由新視野健康公司開發的CerviClear測試，是世界上第一個基於尿液的HPV檢測和宮頸癌篩查測試。

它完成了無創的家庭尿液自我取樣，是唯一完全覆蓋所有14種高危HPV病毒的解決方案。由於該產品已經獲得了CE標誌，因此有資格在香港和大灣區推出。

消費者對宮頸癌的認識不斷提高，在預測期內推動了全球宮頸癌診斷市場的成長。

宮頸癌是最容易預防的癌症之一，它每年在印度婦女中造成近77000人死亡。例如，2023年4月，致力於促進癌症認識、預防和早期檢測的非營利組織- 癌症意識預防和早期檢測信託基金（CAPED）與羅氏診斷印度公司簽署了一份合作備忘錄（MoU）。

與CAPED的關係是羅氏診斷印度公司最近的一項計劃，旨在消除與該疾病相關的社會污名，提高對宮頸癌檢查的認識。羅氏診斷印度公司致力於在國際上降低宮頸癌的發病率。

診斷測試的高成本在預測期內阻礙了全球宮頸癌診斷市場的成長。

宮頸癌診斷測試的價格會因幾個變量而不同，包括特定的測試、地點、醫療機構的環境和現有的醫療系統。巴氏試驗的費用從20美元到100美元不等，這取決於地方和醫療專業人士。

此外，HPV DNA測試的費用從50美元到200美元或更多，取決於實驗室和所採用的精確測試技術。陰道鏡檢查的費用可能在200美元到800美元之間，取決於地區、醫療專業人員和檢查期間進行的任何額外程序。

COVID-19影響分析

COVID-19大流行病對宮頸癌診斷市場產生了重大影響。這場大流行給醫療系統帶來了壓力，限制了宮頸癌診斷服務的提供。

診斷測試的延遲，如巴氏塗片測試、HPV測試、陰道鏡檢查和活檢，被認為是由於缺乏資源、醫療機構負擔過重以及工作人員被轉用於COVID-19應對行動。

截至2023年，COVID-19的情況正在恢復，所有病人都可以進入醫療機構，推動了宮頸癌診斷市場的發展。

俄羅斯-烏克蘭衝突分析

俄烏戰爭對宮頸癌診斷市場的影響是複雜和多方面的。人們可能因戰鬥而流離失所，交通可能中斷，並可能設立軍事檢查站。這些障礙可能會限制人們進入醫療設施，使人們難以獲得及時的宮頸癌診斷和其他醫療服務。

此外，在衝突時期，醫療資源和努力被重新定向，以集中於創傷護理、應急反應和緊急醫療需求。這促使公共衛生措施減少，如宣傳活動和宮頸癌篩查計劃，這將降低篩查率並推遲診斷。

Market Overview

The Global Cervical Cancer Diagnostics Market size reached USD 8.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 13 billion by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.

A variety of tests and techniques are employed in the diagnosis and monitoring of cervical cancer and precancerous diseases as part of cervical cancer diagnostics. Additional procedures, such as lymph node biopsy, cystoscopy, proctoscopy or imaging tests like PET-CT (positron emission tomography-computed tomography), are carried out to ascertain the stage of cervical cancer.

Market Dynamics

Active Major Players and Cervical Cancer Diagnostic Product Launches are Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

For women, cervical cancer is a typically malignant tumor. In recent years, there has been an apparent trend of rejuvenation along with an increase in morbidity and mortality. The only cancer that has a clear etiology and may be cured with early detection is cervical cancer. For instance, the CerviClear test, developed by New Horizon Health, is the world's first urine-based HPV detection and cervical cancer screening test.

It accomplishes non-invasive home-based urine self-sampling and is the only solution that completely covers all 14 high-risk HPV viruses. The product is eligible to be introduced in Hong Kong and the Greater Bay Area because it already possesses a CE Mark.

The Growing Awareness Among Consumers About Cervical Cancer is Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

Cervical cancer is one of the most preventable cancers, it accounts for nearly 77,000 deaths among Indian women each year. For instance, in April 2023, the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India signed a Memorandum of Understanding (MoU).

The relationship with CAPED is one recent initiative by Roche Diagnostics India to remove the societal stigma associated with the disease and raise awareness about cervical cancer screening. Roche Diagnostics India is dedicated to reducing the incidence of cervical cancer internationally.

The High Cost of Diagnostic Tests is Hampering the Global Cervical Cancer Diagnostics Market Growth in the Forecast Period.

The price of cervical cancer diagnostic tests can vary depending on several variables, including the particular test, location, the environment for the medical facility and the healthcare system in existence. Pap tests can cost from $20 and $100, depending place and healthcare professionals.

In addition, HPV DNA tests cost from $50 to $200 or more, depending on the lab and the precise testing technique employed. A colposcopy operation might cost between $200 and $800, depending on the area, the healthcare professional and any extra procedures carried out during the examination.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cervical cancer diagnostics market. The pandemic has put pressure on healthcare systems, which has restricted the availability of cervical cancer diagnostic services.

Delays in diagnostic testing, such as Pap smear tests, HPV tests, colposcopies and biopsies, have been attributed to a lack of resources, overburdened healthcare institutions and the redirection of workers to COVID-19 response operations.

As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities driving the cervical cancer diagnostics market.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the cervical cancer diagnostics market is complex and multifaceted. People may be displaced by the combat, transportation may be disrupted, and military checkpoints may be set up. These obstacles may limit access to medical facilities, making it difficult for people to get prompt cervical cancer diagnoses and other healthcare services.

In addition, healthcare resources and efforts were redirected during times of conflict to focus on trauma care, emergency response and urgent medical needs. This results in fewer public health measures, such as awareness campaigns and cervical cancer screening programs, which would lower screening rates and postpone diagnosis.

Segment Analysis

The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, end-user and region.

The HPV DNA Test Segment is Expected to Hold the 2nd Dominant Position in the Market Over the Forecast Period.

The HPV DNA test segment accounted for the 2nd highest market stake accounting for approximately 27.6% of the cervical cancer diagnostics market in 2022. An HPV test examines a sample of cells to see if they have a high-risk form of the virus. If such an infection persists for a long time, it may alter cervical cells and result in cervical cancer.

For instance, in September 2022, to test for high-risk HPV types in individuals, Mylab Discovery Solutions introduced the "PathoDetect HPV Detection Test," a real-time PCR-based screening tool. 'PathoDetect HPV Detection Test' is a regulatory authority-approved test that finds and distinguishes the presence of high-risk HPV strains, such as strains 16 and 18, which are responsible for the majority of cervical cancers.

Geographical Analysis

Increasing Collaborations and Partnerships Among the Key Players, Increasing Prevalence of Cervical Cancer and Advancement in Cervical Cancer Diagnostics Dominate the North American Region.

North America is expected to dominate the cervical cancer diagnostics market, accounting for around 38.9% of the market share. As per the article published in the International Journal of Gynecological Cancer in 2022, when examining the trends over time, it was discovered that the prevalence of cervical cancer in its remote stages increased annually at a rate of 1.3% (p 0.001). Cervical adenocarcinoma has the highest growth, with an average yearly percent change of 2.9% (p 0.001).

White women in the South aged 40-44 have the biggest increase in distant cervical cancer at a rate of 4.5% annually (p0.001), according to an intersecting analysis of race, location and age.

Competitive Landscape

The major global players in the market include: QIAGEN Becton, Dickinson and Company F. Hoffmann-La Roche Ltd. Guided Therapeutics Olympus Cardinal Health Siemens Healthcare Hologic, Inc. Quest Diagnostics Abbott Laboratories among others.

Why Purchase the Report?

To visualize the global cervical cancer diagnostics market segmentation based on the test type, age group, distribution channel and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Cervical Cancer Diagnostics Market Report Would Provide Approximately 61 Tables, 60 Figures and 195 pages.

Target Audience 2023

Manufacturers / Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Test Type
3.2. Snippet by Age Group
3.3. Snippet by Distribution Channel
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Incidence of Cervical Cancer
- 4.1.2. Restraints
  - 4.1.2.1. High cost of diagnostic tests
- 4.1.3. Opportunity
  - 4.1.3.1. Technological advances
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 9.1.2. Market Attractiveness Index, By Test Type
9.2. Pap Smear Test*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. HPV DNA Test
9.4. Coloscopy
9.5. EEC Test
9.6. Others

10. By Age Group

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.1.2. Market Attractiveness Index, By Age Group
10.2. Below 21*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. 21-29
10.4. 30-65
10.5. 65 and Above

11. By Distribution Channel

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Hospital Pharmacies
11.4. E-Commerce

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.6.1. The U.S.
  - 12.2.6.2. Canada
  - 12.2.6.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.6.1. Germany
  - 12.3.6.2. The U.K.
  - 12.3.6.3. France
  - 12.3.6.4. Italy
  - 12.3.6.5. Spain
  - 12.3.6.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.6.1. Brazil
  - 12.4.6.2. Argentina
  - 12.4.6.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.6.1. China
  - 12.5.6.2. India
  - 12.5.6.3. Japan
  - 12.5.6.4. Australia
  - 12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. QIAGEN*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Becton, Dickinson and Company
14.3. F. Hoffmann-La Roche Ltd.
14.4. Guided Therapeutics
14.5. Olympus
14.6. Cardinal Health
14.7. Siemens Healthcare
14.8. Hologic, Inc.
14.9. Quest Diagnostics
14.10. Abbott Laboratories

LIST NOT EXHAUSTIVE